OptimizeRx
OPRX
29 hedge funds and large institutions have $48.3M invested in OptimizeRx in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1,600% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 1
127% more capital invested
Capital invested by funds: $21.3M → $48.3M (+$27M)
123% more funds holding
Funds holding: 13 → 29 (+16)
5.33% more ownership
Funds ownership: 17.71% → 23.04% (+5.3%)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
Top Sellers
OPRX Hedge Fund Activity: Q3 2018 in Review
29 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q3 2018, worth a combined $48.3M — up 127% from $21.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OPRX positions and 1 closed out — a net gain of 16 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $3.64M. The largest seller was Wolverine Asset Management, cutting an estimated $1.23M.
- 29 institutional investors held OptimizeRx (OPRX) as of Q3 2018, up from 13 in Q2 2018.
- Funds reported $48.3M of OptimizeRx stock for Q3 2018, up 127% quarter-over-quarter.
- 17 funds opened new OptimizeRx positions in Q3 2018 and 1 closed out, a net change of +16 holders.
- The largest OptimizeRx buyer in Q3 2018 was Vanguard Group, an estimated $3.64M added.
- The largest OptimizeRx seller in Q3 2018 was Wolverine Asset Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2018.